Raynaud's phenomenon: pathogenesis and management
- PMID:18656283
- DOI: 10.1016/j.jaad.2008.06.004
Raynaud's phenomenon: pathogenesis and management
Abstract
Raynaud's phenomenon is a common clinical disorder for which patients frequently seek the expertise and care of dermatologists. It is manifested by recurrent vasospasm of the fingers and toes, often associated with exposure to cold temperature or emotional stress. The phenomenon is named after Maurice Raynaud, who, as a medical student, defined the first case in 1862 as episodic, symmetric, acral vasospasm characterized by pallor, cyanosis, suffusion, and a sense of fullness or tautness, which may be painful. Despite more than 140 years of research, the pathophysiology of Raynaud's phenomenon continues to elude investigators. Accordingly, although many pharmacologic treatments have been reported, there is still no cure or gold standard therapy. Further, response to treatment varies and is difficult to predict. Recently, there has been renewed interest in finding the pathogenetic mechanisms of Raynaud's phenomenon, an effort that has led to more potential targeted therapeutics. The purpose of this review is to discuss recent breakthroughs in the pathogenesis and treatment of Raynaud's phenomenon.
Similar articles
- Treatment of Raynaud's phenomenon.García-Carrasco M, Jiménez-Hernández M, Escárcega RO, Mendoza-Pinto C, Pardo-Santos R, Levy R, Maldonado CG, Chávez GP, Cervera R.García-Carrasco M, et al.Autoimmun Rev. 2008 Oct;8(1):62-8. doi: 10.1016/j.autrev.2008.07.002. Epub 2008 Aug 8.Autoimmun Rev. 2008.PMID:18692160Review.
- Raynaud's syndrome: diagnosis and treatment.Whitaker L, Kelleher A.Whitaker L, et al.J Vasc Nurs. 1994 Mar;12(1):10-3.J Vasc Nurs. 1994.PMID:7748770
- Raynaud's phenomenon.O'connor CM.O'connor CM.J Vasc Nurs. 2001 Sep;19(3):87-92; quiz 93-4. doi: 10.1067/mvn.2001.117786.J Vasc Nurs. 2001.PMID:11533581Review.
- [Raynaud's phenomena: diagnostic and treatment study].Priollet P.Priollet P.Rev Prat. 1998 Oct 1;48(15):1659-64.Rev Prat. 1998.PMID:9814067Review.French.
- Pathogenesis of Raynaud's phenomenon.Herrick AL.Herrick AL.Rheumatology (Oxford). 2005 May;44(5):587-96. doi: 10.1093/rheumatology/keh552. Epub 2005 Mar 1.Rheumatology (Oxford). 2005.PMID:15741200Review.
Cited by
- Alpha-blockers: the magic pill for endourology-The great delusion.Kronenberg P.Kronenberg P.World J Urol. 2024 Feb 29;42(1):109. doi: 10.1007/s00345-024-04785-w.World J Urol. 2024.PMID:38421483Review.
- Recent achievements in the management of Raynaud's phenomenon.Baumhäkel M, Böhm M.Baumhäkel M, et al.Vasc Health Risk Manag. 2010 Apr 15;6:207-14. doi: 10.2147/vhrm.s5255.Vasc Health Risk Manag. 2010.PMID:20407628Free PMC article.Review.
- Cold sensitivity and associated factors: a nested case-control study performed in Northern Sweden.Stjernbrandt A, Carlsson D, Pettersson H, Liljelind I, Nilsson T, Wahlström J.Stjernbrandt A, et al.Int Arch Occup Environ Health. 2018 Oct;91(7):785-797. doi: 10.1007/s00420-018-1327-2. Epub 2018 May 28.Int Arch Occup Environ Health. 2018.PMID:29808434Free PMC article.
- Toxin for Treating Raynaud Conditions in Hands (The TORCH Study): A Systematic Review and Meta-analysis.Geary E, Wormald JCR, Cronin KJ, Giele HP, Durcan L, Kennedy O, O'Brien F, Dolan RT.Geary E, et al.Plast Reconstr Surg Glob Open. 2024 Jun 14;12(6):e5885. doi: 10.1097/GOX.0000000000005885. eCollection 2024 Jun.Plast Reconstr Surg Glob Open. 2024.PMID:38881966Free PMC article.
- Botulinum toxin type A suppresses arterial vasoconstriction by regulating calcium sensitization and the endothelium-dependent endothelial nitric oxide synthase/soluble guanylyl cyclase/cyclic guanosine monophosphate pathway: Anin vitro study.Hu L, Feng Y, Liu W, Jin L, Nie Z.Hu L, et al.Exp Biol Med (Maywood). 2019 Nov;244(16):1475-1484. doi: 10.1177/1535370219878143. Epub 2019 Sep 23.Exp Biol Med (Maywood). 2019.PMID:31547684Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical